In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide.
Please provide the number of patients by treatment for the following disease modifying drugs.
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Copaxone (glatiramer acetate)
Extavia (beta interferon-1b)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Peginterferon beta-1a (Plegridy)
The information requested above has been repeatedly asked for in total 8 times every 4 months. For your information attached the last 4 in date order:
The last request from the previous year’s request is published here: https://www.royalsurrey.nhs.uk/ms-drugs/
The most recent request 4116 2017 is also published here:
The latest request has been considered and has been deemed vexatious under Section 14(1) for the Freedom of Information Act 2000.
The Information Commissioner recognises that dealing with the unreasonable requests can place a strain on resources and get in the way of delivering mainstream services or answering legitimate requests. Section 14 (1) is designed to protect public authorities by allowing them to refuse any requests which have the potential to cause disproportionate or unjustified level of disruption, irritation or distress.
A request which would not normally be regarded as vexatious in isolation may assume that quality once considered in context. Submitting frequent repeat requests that have been answered and published previously places a strain on the Trust resources, and the most recent request is contributing to that aggregated burden.